Regenerating Health

Transforming the lives of patients with insulin-requiring diabetes

Developing a Functional Cure for Type 1 Diabetes

ViaCyte is a regenerative medicine company focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for all type 1 diabetes and a next-generation treatment for insulin-requiring type 2 diabetes.

ViaCyte is committed to delivering transformative cell replacement therapies for insulin-requiring diabetes.

ViaCyte’s Product Pipeline

The PEC-Direct and PEC-Encap product candidates are in clinical trials for type 1 diabetes.

PEC-Direct

PEC-Direct is being developed for patients with type 1 diabetes who are at the highest risk of life-threatening acute complications.

PEC-Encap

PEC-Encap is being developed as a potential functional cure for type 1 diabetes.

PEC-QT

The PEC-QT program is partnered with CRISPR Therapeutics to develop a next-generation therapy for all insulin-requiring diabetes.

Breakthrough Technologies

ViaCyte’s pluripotent stem cell-based technologies are designed to address the limitations of donor islet transplants and represent a major advance in the development of a functional cure for type 1 diabetes. ViaCyte’s implantable medical devices are designed to contain our cell replacement therapies and allow for cell survival and function. Together, these technologies have the potential to create leading cell replacement therapies designed to functionally cure human diseases.

ViaCyte has continually broken new ground in medical device engineering, stem cell research, and cell therapy scaling and manufacturing.

Our latest news

Aug 13, 2020 Press Releases

ViaCyte Appoints Dr. Manasi Sinha Jaiman as Vice President, Clinical Development

Sign up for updates

To have our press releases and major updates sent to you, please provide your name and email address.